Zobrazit v EDS

A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke

Uloženo v:
Podrobná bibliografie
Název: A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Transplantation in Patients With Ischemic Stroke
Autoři: Gyeong Joon Moon, Young Hwan Ahn, Jiman Hong, Oh Young Bang, Phil Hyu Lee, Jin Soo Lee
Přispěvatelé: JIN SOO LEE, JI MAN HONG, GYEONG JOON MOON, PHIL HYU LEE, YOUNG HWAN AHN, OH YOUNG BANG, Lee, Phil Hyu
Zdroj: Stem Cells. 28:1099-1106
Informace o vydavateli: Oxford University Press (OUP), 2010.
Rok vydání: 2010
Témata: Adult, Male, Middle Cerebral Artery/surgery, Autologous/adverse effects, Cells, Neurogenesis, Stem cells, Mesenchymal Stem Cell Transplantation, Transplantation, Autologous, 03 medical and health sciences, Clinical trials, 0302 clinical medicine, Humans, Cells, Cultured, Mesenchymal Stem Cell Transplantation*/adverse effects, Aged, Transplantation, Cultured, Infarction, Middle Cerebral Artery, Middle Aged, 3. Good health, Stroke, Survival Rate, Treatment Outcome, Infarction, Mesenchymal stem cells, Female, Follow-Up Studies
Popis: We previously evaluated the short-term follow-up preliminary data of mesenchymal stem cells (MSCs) transplantation in patients with ischemic stroke. The present study was conducted to evaluate the long-term safety and efficacy of i.v. MSCs transplantation in a larger population. To accomplish this, we performed an open-label, observer-blinded clinical trial of 85 patients with severe middle cerebral artery territory infarct. Patients were randomly allocated to one of two groups, those who received i.v. autologous ex vivo cultured MSCs (MSC group) or those who did not (control group), and followed for up to 5 years. Mortality of any cause, long-term side effects, and new-onset comorbidities were monitored. Of the 52 patients who were finally included in this study, 16 were the MSC group and 36 were the control group. Four (25%) patients in the MSC group and 21 (58.3%) in the control group died during the follow-up period, and the cumulative surviving portion at 260 weeks was 0.72 in the MSC group and 0.34 in the control group (log-rank; p = .058). Significant side effects were not observed following MSC treatment. The occurrence of comorbidities including seizures and recurrent vascular episodes did not differ between groups. When compared with the control group, the follow-up modified Rankin Scale (mRS) score was decreased, whereas the number of patients with a mRS of 0–3 increased in the MSC group (p = .046). Clinical improvement in the MSC group was associated with serum levels of stromal cell-derived factor-1 and the degree of involvement of the subventricular region of the lateral ventricle. Intravenous autologous MSCs transplantation was safe for stroke patients during long-term follow-up. This therapy may improve recovery after stroke depending on the specific characteristics of the patients.
Druh dokumentu: Article
Popis souboru: 1099~1106
Jazyk: English
ISSN: 1549-4918
1066-5099
DOI: 10.1002/stem.430
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/20506226
https://stemcellsjournals.onlinelibrary.wiley.com/doi/10.1002/stem.430
https://pubmed.ncbi.nlm.nih.gov/20506226/
https://onlinelibrary.wiley.com/doi/abs/10.1002/stem.430
http://onlinelibrary.wiley.com/doi/10.1002/stem.430/full
https://yonsei.pure.elsevier.com/en/publications/a-long-term-follow-up-study-of-intravenous-autologous-mesenchymal
https://europepmc.org/article/MED/20506226
Rights: OUP Standard Publication Reuse
CC BY NC ND
Přístupové číslo: edsair.doi.dedup.....d40166689c62e88f886aab24bd70ddf8
Databáze: OpenAIRE
Popis
Abstrakt:We previously evaluated the short-term follow-up preliminary data of mesenchymal stem cells (MSCs) transplantation in patients with ischemic stroke. The present study was conducted to evaluate the long-term safety and efficacy of i.v. MSCs transplantation in a larger population. To accomplish this, we performed an open-label, observer-blinded clinical trial of 85 patients with severe middle cerebral artery territory infarct. Patients were randomly allocated to one of two groups, those who received i.v. autologous ex vivo cultured MSCs (MSC group) or those who did not (control group), and followed for up to 5 years. Mortality of any cause, long-term side effects, and new-onset comorbidities were monitored. Of the 52 patients who were finally included in this study, 16 were the MSC group and 36 were the control group. Four (25%) patients in the MSC group and 21 (58.3%) in the control group died during the follow-up period, and the cumulative surviving portion at 260 weeks was 0.72 in the MSC group and 0.34 in the control group (log-rank; p = .058). Significant side effects were not observed following MSC treatment. The occurrence of comorbidities including seizures and recurrent vascular episodes did not differ between groups. When compared with the control group, the follow-up modified Rankin Scale (mRS) score was decreased, whereas the number of patients with a mRS of 0–3 increased in the MSC group (p = .046). Clinical improvement in the MSC group was associated with serum levels of stromal cell-derived factor-1 and the degree of involvement of the subventricular region of the lateral ventricle. Intravenous autologous MSCs transplantation was safe for stroke patients during long-term follow-up. This therapy may improve recovery after stroke depending on the specific characteristics of the patients.
ISSN:15494918
10665099
DOI:10.1002/stem.430